Study of HRS-5041 with other drugs for advanced prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 to 80 years old (18 to 80 for the first part of the study).
- You must have prostate cancer that is adenocarcinoma (the most common type) and it has spread or is advanced.
- You must be able to provide a blood sample for genetic testing and give permission for the study.
- You must be in good enough health to carry out daily activities (ECOG score 0 or 1) and expected to live at least 12 more weeks.
- You must use effective birth control during the study and for 3 months after the last dose if your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs (HRS-1167 and abiraterone with prednisone) for men with prostate cancer that has spread beyond the prostate. The goal is to see if the combination works better than current treatments.
This trial is testing an investigational drug, HRS-7525, for men with advanced prostate cancer that has spread to other parts of the body. The goal is to see if the drug is safe and effective.
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
This trial tests a new drug called SHR-4394 combined with standard hormone therapy for men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination can help control the cancer.
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.